FDA authorizes Mammoth Bio's high-throughput CRISPR test

Grantee News
January 24, 2022

Mammoth Biosciences has secured an emergency authorization from the FDA for its high-throughput COVID-19 test, which is powered by CRISPR gene-editing enzymes. Source: Fierce Biotech.

Explore More

There is so much more to explore at NIBIB.

Health Topics

Research Topics